MX2009001966A - Metodo de reduccion del daño celular neuronal. - Google Patents

Metodo de reduccion del daño celular neuronal.

Info

Publication number
MX2009001966A
MX2009001966A MX2009001966A MX2009001966A MX2009001966A MX 2009001966 A MX2009001966 A MX 2009001966A MX 2009001966 A MX2009001966 A MX 2009001966A MX 2009001966 A MX2009001966 A MX 2009001966A MX 2009001966 A MX2009001966 A MX 2009001966A
Authority
MX
Mexico
Prior art keywords
neuronal cell
cell damage
subject
combination
pharmaceutical agent
Prior art date
Application number
MX2009001966A
Other languages
English (en)
Inventor
David J Poulsen
Thomas Frederick Rau
Original Assignee
Univ Montana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montana filed Critical Univ Montana
Publication of MX2009001966A publication Critical patent/MX2009001966A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se dirige a un método de reducción de la ocurrencia de daño celular neuronal, inclusive la muerte, causada por la hipoxia y/o isquemia cerebral transiente. El método comprende las etapas de: diagnosticar a un sujeto que tiene una condición hipóxica y/o isquémica cerebral transiente; y dentro de 16 horas después del inicio de la condición, administrar al sujeto una cantidad neuroprotectora de un agente farmacéutico. El agente farmacéutico de preferencia se selecciona del grupo que consiste de: un estimulante del sistema nervioso central (CNSS), neurotransmisor de monoamina, inhibidor de monoamina oxidasa (MAOI), antidepresivo tricíclico (TCA), o una combinación de los mismos. Los agentes preferidos incluyen anfetaminas, metanfetamina, metilfenidato, metilen-dioximetenafetamina, o una combinación de los mismos.
MX2009001966A 2006-08-23 2007-08-15 Metodo de reduccion del daño celular neuronal. MX2009001966A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83997406P 2006-08-23 2006-08-23
PCT/US2007/076034 WO2008024660A2 (en) 2006-08-23 2007-08-15 Method of reducing neuronal cell damage

Publications (1)

Publication Number Publication Date
MX2009001966A true MX2009001966A (es) 2009-06-19

Family

ID=39107537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001966A MX2009001966A (es) 2006-08-23 2007-08-15 Metodo de reduccion del daño celular neuronal.

Country Status (15)

Country Link
US (1) US20100249242A1 (es)
EP (1) EP2053919B1 (es)
JP (1) JP5243428B2 (es)
KR (1) KR101494675B1 (es)
CN (2) CN103479603B (es)
AU (1) AU2007286933B2 (es)
BR (1) BRPI0715633A2 (es)
CA (1) CA2661495C (es)
ES (1) ES2452341T3 (es)
HK (1) HK1131003A1 (es)
IL (1) IL197194A (es)
MX (1) MX2009001966A (es)
RU (1) RU2464977C2 (es)
WO (1) WO2008024660A2 (es)
ZA (1) ZA200901318B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105621A1 (en) * 2006-08-23 2011-05-05 The University Of Montana Method of reducing brain cell damage, inflammation or death
CN110251496A (zh) 2013-09-06 2019-09-20 蒙大拿大学 用卤代烷基胺减少神经元细胞死亡的方法
KR20150080706A (ko) * 2014-01-02 2015-07-10 서울대학교산학협력단 N-말단 법칙 경로의 저해용 조성물 및 방법
WO2018107131A1 (en) * 2016-12-11 2018-06-14 Kempharm, Inc. Methylphenidate-prodrugs, processes of making and using the same
MX2019006670A (es) * 2016-12-11 2019-12-16 Kempharm Inc Composiciones que comprenden profarmacos de metilfenidato, procedimientos para la elaboracion y uso de los mismos.
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JP6753434B2 (ja) 2018-06-13 2020-09-09 ダイキン工業株式会社 ジフルオロエチレンの製造方法
RU2696203C1 (ru) * 2018-09-10 2019-07-31 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики церебральной ишемии
WO2020212948A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3074592A (en) * 1991-11-12 1993-06-15 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
SE520730C2 (sv) * 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US6315995B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
KR20010078734A (ko) * 1998-06-11 2001-08-21 다푸르 가브리에 허혈로부터 뉴론의 보호방법
US7619005B2 (en) * 2000-11-01 2009-11-17 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans with Multiple Sclerosis
US20030232890A1 (en) * 2000-11-01 2003-12-18 Sention, Inc. Methods for treating an impairment in memory consolidation
US20070100000A1 (en) * 2000-11-01 2007-05-03 Epstein Mel H Methods of providing neuroprotection
WO2002039998A2 (en) * 2000-11-01 2002-05-23 Sention, Inc. Methods and compositions for regulating memory consolidation
US20030119884A1 (en) * 2000-11-01 2003-06-26 Epstein Mel H. Methods and compositions for regulating memory consolidation
US20100022658A1 (en) * 2000-11-01 2010-01-28 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans
US20050059743A1 (en) * 2000-11-01 2005-03-17 Sention, Inc. Methods for treating mild cognitive impairment and alzheimer's disease
US20070117869A1 (en) * 2000-11-01 2007-05-24 Cognition Pharmaceuticals Llc Methods for treating coginitive impairment and improving cognition
WO2005000203A2 (en) * 2001-10-31 2005-01-06 Sention, Inc. Methods for treating cognitive impairment and improving cognition
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
KR20050059319A (ko) * 2002-10-31 2005-06-17 센주 세이야꾸 가부시키가이샤 각막 장해 치료제
RU2251429C2 (ru) * 2002-12-30 2005-05-10 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Фармацевтическая композиция для лечения ишемического инсульта и способ лечения
US20040176378A1 (en) * 2003-02-12 2004-09-09 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system
US20050159419A1 (en) * 2003-05-14 2005-07-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage

Also Published As

Publication number Publication date
US20100249242A1 (en) 2010-09-30
KR101494675B1 (ko) 2015-02-23
RU2009110273A (ru) 2010-09-27
CA2661495A1 (en) 2008-02-28
IL197194A (en) 2015-06-30
JP5243428B2 (ja) 2013-07-24
AU2007286933B2 (en) 2013-04-04
CN103479603A (zh) 2014-01-01
CN101516194A (zh) 2009-08-26
CN101516194B (zh) 2015-01-21
AU2007286933A1 (en) 2008-02-28
ES2452341T3 (es) 2014-04-01
BRPI0715633A2 (pt) 2013-07-02
HK1131003A1 (en) 2010-01-15
WO2008024660A3 (en) 2008-11-20
ZA200901318B (en) 2012-07-25
EP2053919A2 (en) 2009-05-06
CN103479603B (zh) 2016-06-22
KR20090059125A (ko) 2009-06-10
IL197194A0 (en) 2009-12-24
CA2661495C (en) 2017-05-02
EP2053919A4 (en) 2012-12-26
JP2010501581A (ja) 2010-01-21
RU2464977C2 (ru) 2012-10-27
WO2008024660A2 (en) 2008-02-28
EP2053919B1 (en) 2013-12-25

Similar Documents

Publication Publication Date Title
MX2009001966A (es) Metodo de reduccion del daño celular neuronal.
TW200619199A (en) 3-carbamoyl-2-pyridone derivatives
BRPI0510305A (pt) composto ou um sal do mesmo, pródroga ou um sal da mesma, agente farmacêutico, método de produção do composto ou um sal do mesmo, inibidor de metaloproteinase de matriz ou um sal do mesmo ou uma pródroga do mesmo, método de inibir uma metaloproteinase de matriz, e, uso de um composto ou de um sal do mesmo ou de uma pródroga do mesmo
ECSP078003A (es) Inhibidores de aspartil proteasas
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
BR0317110A (pt) Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
EP2067467A3 (en) Compositions and methods for treating keratinous substrates
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
MX2007006081A (es) Tetrahidroisoquinolinas 4-fenil-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
EP1698335A4 (en) AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
UY29212A1 (es) Azabenzoxazoles para el tratamiento de trastornos del snc
WO2008103847A3 (en) Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
WO2009118765A8 (en) Novel monoamine re-uptake inhibitor
EP1535922A4 (en) PYRROLOPYRIDINE DERIVATIVE AND ITS USE
WO2010019450A3 (en) Synergizing active compounds for treating inflammation and other conditions
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
DalBó et al. Analysis of the antinociceptive effect of the proanthocyanidin-rich fraction obtained from Croton celtidifolius barks: evidence for a role of the dopaminergic system
WO2004052858A3 (en) Inhibitors of monoamine uptake
TW200508195A (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
MXPA04011835A (es) Tratamiento de combinacion para la depresion y ansiedad.
CO6260011A2 (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del acido 4-hidroxi-4-metil-piperidin-1- carboxilico para el tratamiento del trastorno por estres postraumatico
Sawynok et al. Peripheral interactions between dextromethorphan, ketamine and amitriptyline on formalin-evoked behaviors and paw edema in rats
WO2006002375A3 (en) Method of treating ileus by pharmacological activation of cholinergic receptors
Ono et al. Protective effect of R (-)-1-(benzo [b] thiophen-5-yl)-2-[2-(N, N-diethylamino) ethoxy] ethanol hydrochloride (T-588), a novel cerebral activator, against experimental cerebral anoxia
WO2006133339A3 (en) Monoamine re-uptake inhibitors and methods relating thereto

Legal Events

Date Code Title Description
FG Grant or registration